Pfizer nears $14 billion deal for Medivation

(Reuters) - Pfizer Inc is in advanced talks to acquire U.S. cancer drug company Medivation Inc for close to $14 billion, as it seeks to boost its oncology portfolio, a person familiar with the matter said on Sunday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.